Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Pharmacologic agents that modulate ubiquitin ligase activity to induce protein degradation are a major new class of therapeutic agents, active in a number of hematologic malignancies. However, we currently have a limited understanding of the determinants of activity of these agents and how resistance develops. We developed and used a novel quantitative, targeted mass spectrometry (MS) assay to determine the relative activities, kinetics, and cell-type specificity of thalidomide and 4 analogs, all but 1 of which are in clinical use or clinical trials for hematologic malignancies. Thalidomide analogs bind the CRL4CRBN ubiquitin ligase and induce degradation of particular proteins, but each of the molecules studied has distinct patterns of substrate specificity that likely underlie the clinical activity and toxicities of each drug. Our results demonstrate that the activity of molecules that induce protein degradation depends on the strength of ligase-substrate interaction in the presence of drug, the levels of the ubiquitin ligase, and the expression level of competing substrates. These findings highlight a novel mechanism of resistance to this class of drugs mediated by competition between substrates for access to a limiting pool of the ubiquitin ligase. We demonstrate that increased expression of a nonessential substrate can lead to decreased degradation of other substrates that are critical for antineoplastic activity of the drug, resulting in drug resistance. These studies provide general rules that govern drug-dependent substrate degradation and key differences between thalidomide analog activity in vitro and in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Self-citationPhthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061292 · Cited by 1,319
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature · doi:10.1038/nature14610 · Cited by 863
Self-citationAnticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
Han, T., Goralski, M., Gaskill, N., Capota, E., Kim, J., Ting, T. C., Xie, Y., Williams, N. S., & Nijhawan, D. (2017) · Science · doi:10.1126/science.aal3755 · Cited by 762
A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
Matyskiela, M. E., Lu, G., Ito, T., Pagarigan, B., Lu, C.-C., Miller, K., Fang, W., Wang, N.-Y., Nguyen, D., Houston, J., et al. (2016) · Nature · doi:10.1038/nature18611 · Cited by 701
Gandhi, A. K., Kang, J., Havens, C. G., Conklin, T., Ning, Y., Wu, L., Ito, T., Ando, H., Waldman, M. F., Thakurta, A., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12708 · Cited by 619
Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
Sievers, Q. L., Petzold, G., Bunker, R. D., Renneville, A., Słabicki, M., Liddicoat, B. J., Abdulrahman, W., Mikkelsen, T., Ebert, B. L., & Thomä, N. H. (2018) · Science · doi:10.1126/science.aat0572 · Cited by 537
Self-citation
Research works printed but not linked: 15
- Fink, 2015, The novel mechanism of lenalidomide activity, Blood, 126, 2366, 10.1182/blood-2015-07-567958 · DOI · Paper page
- Heintel, 2013, High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone, Br J Haematol, 161, 695, 10.1111/bjh.12338 · DOI · Paper page
- Gillette, 2013, Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry, Nat Methods, 10, 28, 10.1038/nmeth.2309 · DOI · Paper page
- Ippoliti, 2016, Automated microchromatography enables multiplexing of immunoaffinity enrichment of peptides to greater than 150 for targeted MS-Based Assays, Anal Chem, 88, 7548, 10.1021/acs.analchem.6b00946 · DOI
- Kuhn, 2012, Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma, Mol Cell Proteomics, 11, M111.013854, 10.1074/mcp.M111.013854 · DOI · Paper page
- Whiteaker, 2011, Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry, Mol Cell Proteomics, 10, M110.005645, 10.1074/mcp.M110.005645 · DOI · Paper page
- Machleidt, 2015, NanoBRET–a novel BRET platform for the analysis of protein-protein interactions, ACS Chem Biol, 10, 1797, 10.1021/acschembio.5b00143 · DOI · Paper page
- Zhu, 2011, Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide, Blood, 118, 4771, 10.1182/blood-2011-05-356063 · DOI · Paper page
- Greenberg, 2013, Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels, Eur J Haematol, 91, 504, 10.1111/ejh.12192 · DOI
- Schuster, 2014, The clinical significance of cereblon expression in multiple myeloma, Leuk Res, 38, 23, 10.1016/j.leukres.2013.08.015 · DOI · Paper page
- Meyers, 2017, Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells, Nat Genet, 49, 1779, 10.1038/ng.3984 · DOI · Paper page
- Petzold, 2016, Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase, Nature, 532, 127, 10.1038/nature16979 · DOI · Paper page
- Dimopoulos, 2019, Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma, Leuk Lymphoma, 60, 180, 10.1080/10428194.2018.1466290 · DOI
- Krönke, 2017, IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM), Leukemia, 31, 1363, 10.1038/leu.2016.384 · DOI · Paper page
- Zhu, 2014, Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma, Blood, 124, 536, 10.1182/blood-2014-02-557819 · DOI · Paper page
Cited by
Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials
Patton, E. E., Zon, L. I., & Langenau, D. M. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00210-8 · Cited by 567
Targeted protein degradation: from mechanisms to clinic
Tsai, J. M., Nowak, R. P., Ebert, B. L., & Fischer, E. S. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00729-9 · Cited by 438
Self-citationThe CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K
Słabicki, M., Kozicka, Z., Petzold, G., Li, Y.-D., Manojkumar, M., Bunker, R. D., Donovan, K. A., Sievers, Q. L., Koeppel, J., Suchyta, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2374-x · Cited by 433
Self-citationRapid and direct control of target protein levels with VHL-recruiting dTAG molecules
Nabet, B., Ferguson, F. M., Seong, B. K. A., Kuljanin, M., Leggett, A. L., Mohardt, M. L., Robichaud, A., Conway, A. S., Buckley, D. L., Mancias, J. D., et al. (2020) · doi:10.1101/2020.03.13.980946 · Cited by 312
Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide
Jan, M., Scarfò, I., Larson, R. C., Walker, A., Schmidts, A., Guirguis, A. A., Gasser, J. A., Słabicki, M., Bouffard, A. A., Castano, A. P., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb6295 · Cited by 267
Self-citation
Metadata
- Authors
- Sperling, A. S., Burgess, M., Keshishian, H., Gasser, J. A., Bhatt, S., Jan, M., Słabicki, M., Sellar, R. S., Fink, E. C., Miller, P. G., Liddicoat, B. J., Sievers, Q. L., Sharma, R., Adams, D. N., Olesinski, E. A., Fulciniti, M., Udeshi, N. D., Kuhn, E., Letai, A., Munshi, N. C., Carr, S. A., & Ebert, B. L.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2019-07-11
- Volume
- 134
- Issue
- 2
- Pages
- 160-170
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2943602952
- Cited by
- 64
- References
- 27
- FWCI
- 2.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs. https://app.cochat.ai/papers/10.1182/blood.2019000789
- The paper
- Sperling, A. S., Burgess, M., Keshishian, H., Gasser, J. A., Bhatt, S., Jan, M., Słabicki, M., Sellar, R. S., Fink, E. C., Miller, P. G., Liddicoat, B. J., Sievers, Q. L., Sharma, R., Adams, D. N., Olesinski, E. A., Fulciniti, M., Udeshi, N. D., Kuhn, E., Letai, A., . . . Ebert, B. L. (2019). Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs. Blood. https://doi.org/10.1182/blood.2019000789
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.